EUCTR2014-001795-53-GR进行中（未招募）1 期
A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Histologically confirmed unilateral primary invasive adenocarcinoma of the breast
- •? Estrogen receptor-positive and/or progesterone receptor-positive, HER2-negative breast cancer
- •? Patient is after surgical resection of the tumor where tumor was removed completely with the final surgical
- •specimen microscopic margins free from tumor and with available archival tumor tissue from the surgical
- •? Patient who received adjuvant chemotherapy and have AJCC 8th edition Prognostic Stage Group III
- •tumor; or patient who received neoadjuvant chemotherapy and have 1 or more ipsilateral axillary lymph nodes with residual tumor metastases greater than 2.0 mm in lymph node(-s) and residual tumor greater than 10.0 mm in breast tissue
- •? Patient has completed multi-agent adjuvant or neoadjuvant chemotherapy of = 4 cycles or = 12 weeks which included taxanes prior to screening
- •? Patient has completed adjuvant radiotherapy (if indicated) prior to screening
- •? Patient may already have initiated adjuvant endocrine therapy (ET) at the time of randomization, but randomization must take place within 52 weeks of date of initial histological diagnosis of breast cancer and within 12 weeks of initiating ET
- •? ECOG Performance Status 0 or 1
- •? Adequate bone marrow and organ function
- •? Sodium, potassium, phosphorus, magnesium and total calcium laboratory values within normal limits
- •? QTcF interval < 450 msec and mean resting heart rate 50-90 bpm
- •Other inclusion criteria as per full protocol may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1200
排除标准
- •? Prior treatment with CDK4/6 inhibitor
- •? Prior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last 2 years
- •? Prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin or 900
- •mg/m² or more for epirubicin
- •? Distant metastases of breast cancer beyond regional lymph nodes
- •? Patient has not recovered from clinical and laboratory acute toxicities of chemotherapy, radiotherapy and surgery
- •? Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality, or clinically
- •significant cardiac arrhythmias
- •? Uncontrolled hypertension with systolic blood pressure >160 mmHg
- •? Patient is currently receiving any of the prohibited substances that cannot be discontinued 7 days prior to Cycle 1 Day 1: concomitant medications, herbal supplements, and/or fruits and their juices that are known as strong inhibitors or inducers of CYP3A4/5; medications that have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5; systemic corticosteroids = 2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment; concomitant medications with a
- •known risk to prolong the QT interval and/or known to cause torsades de points that cannot be discontinued
- •or replaced by safe alternative medication.
- •? Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed
- •during the study
- •? Women of child-bearing potential unless they are using highly effective methods of contraception during the study treatment and for 21 days after stopping the study treatment.
研究者
相似试验
招募中
3 期
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerCancerPACTR202402608766452Roche4
尚未招募
3 期
The clinical study assessing safety of medicine containing two antiemetic drugs compared to safety of other antiemetic drugs (aprepitant, oral palonosetron)given with oral dexamethasone when they are administered to prevent nausea,vomiting in cancer patients receiving multiple chemotherapy cyclesCTRI/2012/01/002343Helsinn Healthcare SA400
进行中（未招募）
1 期
Multicenter study to evaluate the effect and safety of oral vancomycin compared with placebo in the prevention of relapse due to Clostridium difficile infection in patients treated with antibiotics administered systemically.Patients at high risk of recurrence due to CDI who require hospitalization and who increase morbidity and mortality from new CDI.MedDRA version: 20.0Level: LLTClassification code 10072994Term: Clostridium difficile infection recurrenceSystem Organ Class: 100000004862EUCTR2019-002677-57-ESDra. Julia Origüen Sabater108
已完成
3 期
A phase III, multicenter, randomized, double-blind placebo-controlled study to assess the efficacy and safety of Tocilizumab in subjects with giant cell arteritis.Giant Cell Arteritis10027665Temporal ArteritisNL-OMON39663Hoffmann-La Roche18
招募中
3 期
Clinical Trial on Type 2 diabetes Mellitus (T2DM)CTRI/2023/08/056886Theon Pharma